William Robinson, MD, PhD, first became interested in rheumatology in medical school when he started working with a rheumatologist, as well as several other rheumatology mentors. After completing his residency, he joined the rheumatology fellowship program at Stanford University Medical Center, Palo Alto, Calif., where he earned support for his research from the Rheumatology Research…
CHICAGO—A 49-year-old woman has had RA for eight years. She has a rheumatoid factor reading of 35, an aCCP reading of 160, erythrocyte sedimentation rate of 42, plus erosions. She has been on methotrexate. She tried etanercept for six months, but then it stopped working. She was on 40 mg of adalimumab weekly, but it…
The pathogenesis of and new classification criteria for MAS
Recognizing, reducing risk of bone fractures in pediatric patients with rheumatic disease, taking glucocorticoid therapy
Immunoglobulin superfamily of proteins, CTLA-4 and PD-1, may generate treatments for RA, SLE
Operational, budgetary, financial and human resource responsibilities typically fall under practice managers’ domains
New research compares pathogenic immune response in SLE with immune response that contributes to atherosclerotic plaque
Experts highlight research on the overlap in innate and acquired immune responses underlying rheumatic diseases
Gut bacteria may hold clues to breakthrough rheumatic disease treatments
Rheumatology Research Foundation Memorial Lectureship honors work of renowned rheumatologist Stephen Malawista, MD